

Electronic Acknowledgement Receipt

EFS ID:	7718589
Application Number:	09993647
International Application Number:	
Confirmation Number:	1010
Title of Invention:	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
First Named Inventor/Applicant Name:	Bernd Riedl
Customer Number:	23599
Filer:	Csaba Henter/Caitlin Sickler
Filer Authorized By:	Csaba Henter
Attorney Docket Number:	BAYER 18A
Receipt Date:	01-JUN-2010
Filing Date:	27-NOV-2001
Time Stamp:	14:03:43
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P70a-Dunst-et-al-Strahlenther-Onkol-v177-p469.pdf	118016 a3479c411ebdbd83db725c5ed320d13f3dc4f4da	no	5

Warnings:

Information:

2	Information Disclosure Statement (IDS) Filed (SB/08)	P71-EBOS-MultipleCirculation. pdf	396525	no	6
			a2fc5eee7fc02873c7eccf4823309289316d2af7		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	NPL Documents	P71a-Ebrahimi-et-al-Cancer- v101-n12-p2727.pdf	1750542	no	10
			274073b4ab204821b58025b55eb8d94ea76721b0		
Warnings:					
Information:					
4	NPL Documents	P72- EisenPhaseITrialofBAY43-9006S orafenibCombinedwithDacarb azineDTICinMetastaticMelano maPatients.pdf	66103	no	1
			3a7f066aab69cb172c667761be6e3477f0a3857d		
Warnings:					
Information:					
5	NPL Documents	P73-EISENETAL- SorafenibAdvancedMelanoma. pdf	1392300	no	14
			f99cd649a550b3eef8d1533f5821ea8a169f6448		
Warnings:					
Information:					
6	NPL Documents	P74- EisenhauerImpactofNewNon- CytotoxicsintheTreatmentofOv arianCancer.pdf	560154	no	5
			be9b50cb492a69516f1fb58fa5fb13e1aea577e6		
Warnings:					
Information:					
7	NPL Documents	p75.pdf	178921	no	10
			905b68e3e38f9a738d4e278ba77677210d0391a2		
Warnings:					
Information:					
8	NPL Documents	P76EltingBiomarkersassociated withclinicaloutcomes.pdf	57666	no	2
			304c0e15483657ea107c07c1f7544df5f6daa3b7		
Warnings:					
Information:					
9	NPL Documents	P77- EscudierRandomizedPhaseIIITri aloftheRafKinaseandVEGFRInhi bitorSorafenib.pdf	71404	no	1
			753890aeb5577b3cfc9cbf5940b45db5d130347		
Warnings:					
Information:					
10	NPL Documents	P78-ESCUDIERETAL- SorafenibAdvancedClearCell. pdf	1154369	no	17
			8e3544f0fb046a16d67c3b5e6a0b44140eb5155		

Warnings:					
Information:					
11	NPL Documents	P79- EUROPEANMEDICINESAGENCY. pdf	4589363 2c39c7ca5a0ed517f3002da19e4e7669860c1d56	no	63
Warnings:					
Information:					
12	NPL Documents	P79a- FabianetalSmallMoleculeKinase InteractionMap.pdf	1259199 c8cdb79966977460eaeaba3d0136f68245ca2ab97	no	12
Warnings:					
Information:					
13	NPL Documents	P79b-Faderl-et-al-Blood-v15- p4303.pdf	101979 2751f59b9b909f36f8af405ddb2730d049a676d4	no	5
Warnings:					
Information:					
14	NPL Documents	P80-FAIVRE- MolecularBasisforSunitinibEffic acy.pdf	1710238 94c5b43e58848c8fc88ac2cd3fabe7fc33f5af46	no	12
Warnings:					
Information:					
15	NPL Documents	P80a-Fakhari-et-al-J-Ped-Surg- v-37-n4-p582.pdf	7114786 d6189b3315a6b8f58f8cc3eac5b0dcf518a084f3	no	6
Warnings:					
Information:					
16	NPL Documents	P81-FAVARO- TargetedTherapyinRenalCellCa rcinoma.pdf	837301 b5814ae287dee8034d0f56c927255b6421814b65	no	8
Warnings:					
Information:					
17	NPL Documents	P81a-Fiedler-et-al-Blood-v102- n8-p2763.pdf	779982 70c96f825a36e6eb45ed9ed2e5cd2da85b831aef	no	5
Warnings:					
Information:					
18	NPL Documents	P82-Feldmann- NatureImmunology.pdf	289554 372a7e97320229392138134aad4fb3df82e18d5	no	3
Warnings:					
Information:					
19	NPL Documents	P83-FieldsVirology.pdf	313503 81b89ef6c0d6004ed6724ac31bbdf967c0fe9a54	no	8

Warnings:					
Information:					
20	NPL Documents	P84-FLAHERTYETAL- PhaselOralMultikinase.pdf	709902	no	7
			9fed8a0401e825c89369c820537f2fb2f96944f8		
Warnings:					
Information:					
Total Files Size (in bytes):			23451807		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					